Argireline: the complete research guide.

Argireline, or acetyl hexapeptide-3, is a six-amino-acid synthetic peptide sold as a “topical Botox alternative.” The 2002 founding paper reported a 30% reduction in wrinkle depth at 30 days. Trials since then show modest, measurable effects. The 500 Dalton skin-penetration ceiling caps what any topical acetyl hexapeptide-3 can do.

What is Argireline?

Argireline is the trade name for acetyl hexapeptide-3. It's a six-amino-acid peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂. The molecular weight is roughly 889 daltons. Daltons are the standard mass unit chemists use for small molecules.

A Spanish biotech firm called Lipotec patented it in the early 2000s. Lubrizol acquired Lipotec, so today it's a Lubrizol ingredient. You'll also see it labeled acetyl hexapeptide-8 on cosmetics packaging. That's the same molecule under a newer ingredient-list nomenclature, not a different peptide.

The design logic ran like this. Botulinum toxin type A, sold as Botox, works by cutting up SNAP-25, a protein that lets nerve cells release acetylcholine onto muscles. No SNAP-25, no muscle contraction, no wrinkle.

A small peptide blocking the same SNAP-25 site without cutting it could, in theory, do a milder version of the same thing. Megighian and colleagues laid out that biochemistry in 2015.

How does the mechanism actually work?

Here's the cellular biology in plain terms. To release a chemical messenger, a nerve cell uses a docking complex called SNARE. Three proteins do the work: SNAP-25, syntaxin-1, and synaptobrevin. Together they fuse the vesicle, the storage bubble, to the cell membrane. That's how acetylcholine gets out and tells the muscle to twitch.

Botox sabotages this by cutting SNAP-25 in half. The cell needs to make new SNAP-25 from scratch, which takes months. That's why a Botox injection lasts so long.

Argireline's pitch is gentler. It binds the SNAP-25 site and physically blocks assembly without cutting anything. The original 2002 Lipotec paper showed this in chromaffin cells, a secretory cell type used as a stand-in for nerve cells in vitro, per Blanes-Mira and colleagues.

The blockade is reversible, and it depends on how much peptide is present. The mechanism makes sense on paper. The hard question is whether enough peptide ever reaches the muscle through your skin.

The 500 Dalton problem.

This is the single biggest constraint on topical delivery, so it's worth examining closely. The skin's outer layer is the stratum corneum, a multilayer of dead corneocytes that works as an effective permeation barrier.

Dermatologists describe this with the 500 Dalton rule: compounds heavier than about 500 Da can't easily permeate intact skin. Bos and Meinardi set that out in 2000.

Argireline weighs 889 Da. That's well above the cutoff. In a standard topical serum, most of the peptide stays on the surface. Only a small fraction makes it to the live skin underneath. An even smaller fraction reaches the depth where muscles contract.

Formulators have tried to fix this. They use penetration enhancers like propylene glycol. They use liposomes, tiny lipid bubbles that wrap the peptide. They use microneedle patches that punch the peptide past the skin barrier.

These help measurably, per An and colleagues in 2019. They don't make the 500 Dalton rule disappear.

What does the published evidence actually show?

Three studies do most of the work in the Argireline literature. We'll walk through each.

Blanes-Mira 2002 is the founding Lipotec paper. The team tested topical Argireline on 10 women for 30 days at 10% concentration. Wrinkle depth dropped roughly 30%.

The catch: the study was small, uncontrolled with no placebo, and run by the company selling the molecule. We found no independent group that has replicated that 30% figure since.

Wang 2013 is the strongest independent trial. Researchers in China ran a randomized vehicle-controlled study on 60 subjects with periocular wrinkles. Participants applied 10% acetyl hexapeptide-3 twice daily for 84 days. Wrinkle depth dropped about 16% vs. baseline, statistically significant. Most later reviews quote that as representative, from Wang and colleagues in 2013.

An 2019 ran a natural experiment on the 500 Dalton rule. The Korean team loaded acetyl hexapeptide-8 into a hyaluronic-acid microneedle patch, whose needles physically pierce the skin barrier.

Wrinkle reduction at 8 weeks came in around 27%, meaningfully better than a topical serum control. Translation: the molecule works when it gets past your skin. Delivery is the bottleneck, not pharmacology.

Pattern across the dozen-plus smaller studies: real, modest wrinkle improvement over 4–12 weeks at 5–10% concentration, with the delivery vehicle doing most of the heavy lifting. Injected Botox typically produces 60–80%+ wrinkle reduction at treated sites. Argireline doesn't approach that. It also isn't nothing.

GHK-Cu (copper peptide alternative)

Tripeptide 3 aa + Cu(II) Endogenous

Argireline standalone is on the Peptriva roadmap but not yet stocked. Our currently stocked copper peptide is GHK-Cu — the copper tripeptide with five decades of peer-reviewed dermatology evidence on collagen synthesis, dermal matrix repair, and antioxidant signaling. See the complete guide for the full mechanism and evidence review.

Browse the catalog

Argireline vs Botox.

The “topical Botox” framing is the marketing engine for Argireline. It's also the most overstated claim in cosmetic dermatology. Let's walk through what the two actually share and what they don't.

They share the target. Both act on SNAP-25. Both reduce acetylcholine release. That's where the similarity stops.

Mechanism. Botox is an enzyme. One toxin molecule can chop up many SNAP-25 molecules in a row. Argireline isn't an enzyme. One peptide binds one SNAP-25 site, then drifts off.

Route. Botox is injected directly into the muscle. Argireline sits on top of skin and tries to seep down. The 500 Dalton barrier we covered above is in the way.

Magnitude. A clinical Botox dose nearly paralyzes the treated muscle for 3–4 months. Published topical Argireline studies reported 10–25% wrinkle reduction in study participants over 8–12 weeks. Reported effects were observed to regress following discontinuation of application.

Regulation. Botox is an FDA-approved prescription drug. Argireline is classified as a cosmetic ingredient.

Argireline shares Botox's biochemical target, but the published literature reports effects at roughly 1–5% of the magnitude. The two aren't pharmacologically equivalent. Argireline is a reversible competitive SNARE inhibitor applied topically. Botox is an irreversible proteolytic enzyme delivered intramuscularly.

Argireline vs the dermal peptide field.

The following summarizes how Argireline compares to the three molecules most often discussed alongside it in the dermatology literature and formulation research.

SNAP-8 (acetyl octapeptide-3)

SNAP-8 is Lubrizol's newer eight-residue extension of the same SNARE-inhibition concept. The manufacturer markets it as higher potency, but its independent evidence base is thinner than Argireline's. Its molecular weight runs about 1100 Da, further above the 500 Dalton threshold.

Commercial preparations commonly co-formulate SNAP-8 with Argireline. We found little independent data showing the combination beats either compound alone.

Matrixyl (palmitoyl pentapeptide-4)

Matrixyl works by a different mechanism. It's a procollagen-fragment-derived peptide that studies characterize as a fibroblast signaling agent for collagen synthesis. Argireline targets dynamic expression lines, the ones neuromuscular contraction produces. Matrixyl has been studied on static, structural wrinkles.

The two peptides are mechanistically orthogonal, and formulators commonly combine them. Matrixyl's palmitoyl fatty-acid tail opens a separate lipid-layer route that studies report improves dermal delivery over aqueous-only vehicles.

GHK-Cu

GHK-Cu has a broader evidence base: five decades of peer-reviewed data on copper-dependent enzyme activity, collagen and elastin synthesis, and antioxidant signaling.

GHK-Cu has been characterized as a dermal-matrix rebuilding agent, meaning structural scaffolding. Argireline has been characterized as a neuromuscular signaling modulator working on expression lines. The two target different parts of skin biology, and formulation research has studied them together.

Formulation parameters in the published literature.

The published Argireline trials used a narrow set of formulation parameters. Those parameters define the whole in vitro and cosmetic-clinical evidence base.

• Concentration studied: 5–10% acetyl hexapeptide-3 or -8. Studies below 5% have not reported measurable effects.
• Delivery vehicles examined: Oil-in-water emulsions, liposomes, microneedle patches, and formulations with penetration enhancers (propylene glycol, ethanol-water co-solvents) have been reported to outperform plain aqueous vehicles in comparative studies.
• Study durations: Published protocols ranged from 28 to 84 days, with peak reported effects at 60–84 days.
• Target sites in trial subjects: Periocular (crow’s feet), forehead, and glabellar zones were the sites evaluated in the published dermatology studies. Thinner skin sites have been associated with larger reported effects in the literature, consistent with reduced barrier depth.
• Co-formulation investigated: Preclinical and clinical formulation studies have examined combinations with SNAP-8, palmitoyl pentapeptide-4 (Matrixyl), GHK-Cu, hyaluronic acid, niacinamide, and retinoids.

Is Argireline safe?

The safety profile is one of the better-documented parts of the Argireline file. Across the published dermatology trials, no serious adverse events have been reported. Skin irritation and contact dermatitis happen at low rates that look more attributable to the vehicle than the peptide itself.

The 889 Da molecular weight that limits efficacy also limits systemic absorption. Published pharmacokinetic data indicate negligible blood-level exposure from topical application, consistent with the 500 Dalton penetration ceiling. Systemic off-target effects from topical cosmetic use have not been reported in the clinical literature.

Regulatory status.

Argireline is regulated as a cosmetic ingredient, not a drug. That's true at the FDA and at equivalent regulators in the EU, UK, Canada, and Australia. The cosmetic framework lets a company claim the product affects the appearance of wrinkles. It blocks any claim that the ingredient changes “the structure or function of the body,” in the FDA's phrasing.

That's why cosmetic labeling says “reduces the appearance of expression lines” rather than “reduces wrinkle depth” on its own. The second framing is a structure-or-function claim. It would reclassify the product as a drug and trigger FDA approval, which Argireline has never been through.

Argireline does not appear on the WADA Prohibited List. It is not a controlled substance. It is commercially available as a cosmetic ingredient.

GHK-Cu (currently stocked)

50 mg ≥99% pure Lyophilized

Argireline is on the roadmap; not yet stocked. Our current copper peptide is GHK-Cu — the copper tripeptide with decades of dermatology RCT evidence on collagen synthesis, dermal matrix repair, and wound healing. Each lot ships with a third-party CoA from an ISO 17025–accredited lab. Mass-spec identity and HPLC purity verified per batch.

Learn more

Frequently asked questions

What is Argireline?

It's the trade name for acetyl hexapeptide-3, a synthetic six-residue peptide. Lipotec, now Lubrizol, developed it in the early 2000s. The sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂. You'll also see it sold as acetyl hexapeptide-8, which is the same molecule under newer ingredient-list naming. It's a topical cosmetic ingredient marketed for expression-line wrinkles.

Argireline vs Botox: what's the actual difference?

Botox is an injected enzyme that chops up SNAP-25, the protein that lets nerves signal muscles. Effect: 3–4 months of near-paralysis. Argireline is a topical peptide that gently blocks the same protein. Effect: maybe 10–25% wrinkle reduction over 8–12 weeks. The two molecules share a target. They don't share magnitude.

Does Argireline actually work?

Published trials report statistically significant but modest effects. Independent randomized studies reported 10–27% wrinkle-parameter reduction over 8–12 weeks at 5–10% topical concentration. The 2002 founding study reported 30%, and it was small, uncontrolled and manufacturer-affiliated. We'd call the evidence base cosmetic-dermatology grade, not pharmaceutical, with effect sizes well below injected botulinum toxin.

Argireline vs Matrixyl vs SNAP-8: which one for what?

Argireline and SNAP-8 are both SNAP-25 mimics for expression-line wrinkles. SNAP-8 is the eight-residue successor. Matrixyl is different: it's a collagen-signaling peptide for static, structural wrinkles. The three aren't interchangeable. You'll often see them formulated together.

Argireline vs GHK-Cu: which has the stronger evidence base?

GHK-Cu has a more extensive evidence base: five decades of peer-reviewed work on copper-dependent enzymes, collagen synthesis and antioxidant signaling. The two peptides target different mechanisms, structural dermal matrix against expression-line neuromuscular signaling. The literature treats them as complementary, not interchangeable. By breadth of evidence, GHK-Cu is far better characterized.

How long did published trials report until measurable effects were observed?

Published dermatology studies used 28–84 day protocols, applying 5–10% acetyl hexapeptide-3 or -8 twice daily. Blanes-Mira 2002 reported initial effects at 30 days. Wang 2013 reported peak effect at 60–84 days.

An 2019 reported measurable wrinkle reduction at 4–8 weeks using a microneedle-patch vehicle. In subjects monitored after the protocol ended, the effects regressed once application stopped.

What does the published literature report on the safety profile?

Across the published dermatology trials, no serious adverse events were reported. Systemic absorption was characterized as negligible, which fits an 889 Da molecule sitting above the 500 Dalton skin-penetration threshold.

Skin irritation and contact dermatitis showed up at low rates across the studies. The incidence looks more attributable to the delivery vehicle than to the peptide itself.